1260P Clinical outcomes of patients with BRAFv⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI